BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11459172)

  • 1. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes.
    Mazzocchi A; Melani C; Rivoltini L; Castelli C; Del Vecchio M; Lombardo C; Colombo MP; Parmiani G
    Cancer Immunol Immunother; 2001 Jun; 50(4):199-211. PubMed ID: 11459172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
    Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni MT; Anichini A; Cascinelli N; Colombo MP; Parmiani G
    Hum Gene Ther; 1994 Sep; 5(9):1139-50. PubMed ID: 7833372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
    Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
    Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine.
    van Elsas A; Aarnoudse C; van der Minne CE; van der Spek CW; Brouwenstijn N; Osanto S; Schrier PI
    J Immunother; 1997 Sep; 20(5):343-53. PubMed ID: 9336741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
    Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo MP; Parmiani G
    Hum Gene Ther; 1996 Oct; 7(16):1955-63. PubMed ID: 8930655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells.
    Yang S; Darrow TL; Seigler HF
    Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of alloreactivity of melanoma by transduction with B7.1.
    Brady MS; Lee F; Eckels DD; Ree SY; Latouche JB; Lee JS
    J Immunother; 2000; 23(3):353-61. PubMed ID: 10838664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.
    Dummer R; Yue FY; Pavlovic J; Geertsen R; Döhring C; Moelling K; Burg G
    Br J Cancer; 1998 May; 77(9):1413-9. PubMed ID: 9652756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
    Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
    Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
    Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
    Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.